Iovance Biotherapeutics Inc
IOVA2.870USD
+0.050+1.77%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.11BMarket Cap
LossP/E TTM
More Details of Iovance Biotherapeutics Inc Company
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. It is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. It also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
Iovance Biotherapeutics Inc Info
Ticker SymbolIOVA
Company nameIovance Biotherapeutics Inc
IPO dateJun 20, 2008
CEOVogt (Frederick G)
Number of employees838
Security typeOrdinary Share
Fiscal year-endJun 20
Address825 Industrial Road
CitySAN CARLOS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94070
Phone16502607120
Websitehttps://www.iovance.com/
Ticker SymbolIOVA
IPO dateJun 20, 2008
CEOVogt (Frederick G)
Company Executives of Iovance Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
464.52K
+6.89%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
215.86K
+1.41%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
105.74K
+6.07%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Dr. Friedrich Graf Finckenstein, M.D.
Dr. Friedrich Graf Finckenstein, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
464.52K
+6.89%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
215.86K
+1.41%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
105.74K
+6.07%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
58.60M
97.75%
Rest of world
1.35M
2.25%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
MHR Fund Management LLC
7.30%
Quogue Capital L.L.C.
7.07%
The Vanguard Group, Inc.
6.05%
BlackRock Institutional Trust Company, N.A.
5.46%
State Street Investment Management (US)
3.35%
Other
70.77%
Shareholders
Shareholders
Proportion
MHR Fund Management LLC
7.30%
Quogue Capital L.L.C.
7.07%
The Vanguard Group, Inc.
6.05%
BlackRock Institutional Trust Company, N.A.
5.46%
State Street Investment Management (US)
3.35%
Other
70.77%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.62%
Hedge Fund
11.35%
Investment Advisor/Hedge Fund
9.44%
Private Equity
7.30%
Venture Capital
7.12%
Research Firm
5.59%
Individual Investor
0.32%
Bank and Trust
0.23%
Pension Fund
0.23%
Other
37.80%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
650
248.97M
62.75%
-52.51M
2025Q2
654
271.34M
81.00%
-28.55M
2025Q1
680
275.16M
84.08%
-27.55M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
MHR Fund Management LLC
28.97M
8.01%
+4.55M
+18.63%
Jun 30, 2025
Quogue Capital L.L.C.
28.07M
7.76%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
25.03M
6.92%
-2.70M
-9.74%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
19.50M
5.39%
-1.03M
-5.02%
Jun 30, 2025
State Street Investment Management (US)
9.89M
2.73%
-1.15M
-10.42%
Jun 30, 2025
Invenomic Capital Management LP
8.29M
2.29%
+2.80M
+51.09%
Jun 30, 2025
Long Focus Capital Management LLC
11.82M
3.27%
+2.57M
+27.78%
Jun 30, 2025
Palo Alto Investors LP
3.43M
0.95%
+218.01K
+6.79%
Jun 30, 2025
Geode Capital Management, L.L.C.
6.19M
1.71%
+220.76K
+3.70%
Jun 30, 2025
BofA Global Research (US)
4.03M
1.11%
+1.52M
+60.87%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Products ETF
1.36%
iShares Genomics Immunology and Healthcare ETF
1.14%
WisdomTree BioRevolution Fund
0.51%
Invesco NASDAQ Future Gen 200 ETF
0.47%
State Street SPDR S&P Biotech ETF
0.23%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco Nasdaq Biotechnology ETF
0.07%
Invesco RAFI US 1500 Small-Mid ETF
0.07%
iShares Biotechnology ETF
0.05%
View more
Virtus LifeSci Biotech Products ETF
Proportion1.36%
iShares Genomics Immunology and Healthcare ETF
Proportion1.14%
WisdomTree BioRevolution Fund
Proportion0.51%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.47%
State Street SPDR S&P Biotech ETF
Proportion0.23%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.14%
ProShares Ultra Nasdaq Biotechnology
Proportion0.11%
Invesco Nasdaq Biotechnology ETF
Proportion0.07%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.07%
iShares Biotechnology ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Iovance Biotherapeutics Inc?
The top five shareholders of Iovance Biotherapeutics Inc are:
MHR Fund Management LLC holds 28.97M shares, accounting for 8.01% of the total shares.
Quogue Capital L.L.C. holds 28.07M shares, accounting for 7.76% of the total shares.
The Vanguard Group, Inc. holds 25.03M shares, accounting for 6.92% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 19.50M shares, accounting for 5.39% of the total shares.
State Street Investment Management (US) holds 9.89M shares, accounting for 2.73% of the total shares.
MHR Fund Management LLC holds 28.97M shares, accounting for 8.01% of the total shares.
Quogue Capital L.L.C. holds 28.07M shares, accounting for 7.76% of the total shares.
The Vanguard Group, Inc. holds 25.03M shares, accounting for 6.92% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 19.50M shares, accounting for 5.39% of the total shares.
State Street Investment Management (US) holds 9.89M shares, accounting for 2.73% of the total shares.
What are the top three shareholder types of Iovance Biotherapeutics Inc?
The top three shareholder types of Iovance Biotherapeutics Inc are:
MHR Fund Management LLC
Quogue Capital L.L.C.
The Vanguard Group, Inc.
MHR Fund Management LLC
Quogue Capital L.L.C.
The Vanguard Group, Inc.
How many institutions hold shares of Iovance Biotherapeutics Inc (IOVA)?
As of 2025Q3, 650 institutions hold shares of Iovance Biotherapeutics Inc, with a combined market value of approximately 248.97M, accounting for 62.75% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -18.25%.
What is the biggest source of revenue for Iovance Biotherapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Iovance Biotherapeutics Inc, amounting to -- and accounting for --% of total revenue.
